Vertex Pharmaceuticals Incorporated

Teva Pharmaceutical Industries – best known as a generic drug leader – has been focused on building an innovative drug portfolio, a key pillar of CEO Richard Francis’s “pivot to growth” strategy. The

In a year that has so far been marked by major changes and upheaval at the US Food and Drug Administration, pharma companies are largely still on track with their expected 2025 approvals and launches.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novartis Inks Four-Year Proteome Resear

Vertex Pharmaceuticals has presented new data on zimislecel that analysts believe reinforce the potential of the off-the-shelf stem cell therapy as a gamechanger for severe type 1 diabetes (T1D). Upda